- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01904565
Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (HYPROSAR)
A Phase I/II Study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hyperthermia would be delivered at Kantonsspital Aarau (KSA) with superficial or deep hyperthermia treatment units as may be appropriate. All patients would undergo a pre-hyperthermia treatment planning and a temperature of around 41.5 Centigrade to 42.5 Centigrade would be aimed during hyperthermia sessions.Hyperthermia would be delivered once a week and the treatment sessions would last for around 60 minutes of active heating.
Proton bean therapy would be carried out at Center of Proton Therapy, Paul Scherrer Institute (PSI), Villigen using scanning beam proton therapy. A preoperative dose of 55 - 60 Gray equivalent (GyE) or those considered for radical treatment, 72-76 GyE would be delivered, 5 days a week at 1.8 - 2 Gy/fr.
On days of both hyperthermia at KSA and proton therapy at PSI, the time interval between the two treatments could be 90 to 150 minutes, taking into consideration the time to travel between the two institutions. Hyperthermia in these days would follow proton beam therapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Niloy R Datta, MD, DNB,
- Phone Number: +41-62 8389559
- Email: niloyranjan.datta@ksa.ch
Study Contact Backup
- Name: Stephan Bodis, MD
- Phone Number: +41-62 838 5371
- Email: stephan.bodis@ksa.ch
Study Locations
-
-
Aargau
-
Aarau, Aargau, Switzerland, CH 5001
- Recruiting
- Kantonsspital Aarau
-
Contact:
- Niloy R Datta, MD, DNB, CCST
- Phone Number: 0041 62 8389559
- Email: niloyranjan.datta@ksa.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histopathologically proven and classified soft tissue sarcoma (STS) as per the WHO classification (2002). For all primary tumours, biopsy would be done within 2 months prior to registration and reviewed by the study pathologist. For all recurrent tumours, if prior biopsy has been done elsewhere, the histopathology would be reviewed by the study pathologist.
Primary STS of extremities, trunk (except intrabdominal) and retroperitoneal which are,
- Deemed inoperable by the study surgeon
- Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
- Patient medically unfit to undergo surgery
- Patient refuses surgery
Recurrent STS extremities and trunk would be eligible if
- Deemed inoperable by the study surgeon
- Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
- Patient medically unfit to undergo surgery
- Patient refuses surgery
- Had not received prior radiotherapy to the proposed site of treatment.
- All patients having extremity STS with stages T2 and G2 or 3 with M0 (Stages IIB and III as per American Joint Committee on Cancer, AJCC 2010), would be included. For patients of STS of trunk, tumours less than 5cm may also be included if they are considered unresectable.
- Age more than 18 years
- Eastern Cooperative Oncology Group,ECOG performance scale 0 and 1
- Female patients must use effective contraception; must not be pregnant or lactating
- Life expectancy of atleast 2 years based on the age and co-morbidities, but excluding diagnosis of STS
- Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
- Willing to travel to Paul Scherrer Institute for proton therapy and to Kantonsspital Aarau for Hyperthermia treatment.
- Agree to comply with the protocol
- Patients must sign a study specific informed consent form prior to registration.
Exclusion Criteria:
- Histopathology of rhabdomyosarcoma, extraosseous Ewing's, primary neuroectodermal tumour, aggressive fibromatosis (desmoids tumours), dermatofibrosarcoma protuberans, gastrointestinal stromal tumours, osteosarcoma, chondrosarcoma, Kaposi's sarcoma or angiosarcoma of scalp/face/neck
- Prior radiotherapy to the site of treatment
- Intrabdominal soft tissue sarcomas
- Use of neoadjuvant chemotherapy prior to radiotherapy or surgery
- Patients with regional nodal metastasis
- Patients with unequivocal distant metastasis
- No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin which are not in the area of the present malignancy or in situ carcinoma of the skin
- No serious medical illness which would prevent informed consent or limit survival to less than 2 years
- Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator would preclude the patient from meeting the study requirements.
- Patients having metal implants, pacemakers or clustered markers
- Patient who had a history of myocardial infarction within the past 12 months
No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Thermoradiotherapy
Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas
Time Frame: 6 months from end of treatment
|
Acute and late morbidities of the treatment would be evaluated according to the CTCAE 4.0 guidelines during and until 6 months after the treatment
|
6 months from end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control
Time Frame: 6 months following the completion of study treatment
|
Imaging response according to RECIST criteria comparing pretreatment MRI versus post treatment MRI taken 4 to 6 weeks after completion of the study treatment.
|
6 months following the completion of study treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local disease free survival
Time Frame: Would be assessed every 6 monthly up to a maximum of 48 months
|
Local disease free survival would be computed using the Kaplan-Meir survival statistics
|
Would be assessed every 6 monthly up to a maximum of 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Niloy R Datta, MD, DNB, Kantonsspital Aarau, Switzerland
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KSA_HYPROSAR1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Hyperthermia and Proton Beam
-
Shin Kong Wu Ho-Su Memorial HospitalUnknownAll Type of Cancers With Bony MetastasisTaiwan
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingResectable Lung Non-Small Cell CarcinomaUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)RecruitingBrain TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8United States
-
Children's Hospital of PhiladelphiaRecruiting
-
Samsung Medical CenterCompletedLiver Neoplasm | Proton Therapy | Portal Vein Tumor ThrombosisKorea, Republic of
-
Loma Linda UniversityActive, not recruiting
-
Massachusetts General HospitalDana-Farber Cancer Institute; National Institutes of Health (NIH)UnknownGerm Cell Tumor | Central Nervous System Germ Cell TumorUnited States
-
National Cancer Center, KoreaCompletedProstate AdenocarcinomaKorea, Republic of
-
Massachusetts General HospitalDana-Farber Cancer Institute; Boston Children's Hospital; National Institutes... and other collaboratorsActive, not recruitingBone Sarcoma | Non-rhabdomyosarcoma Soft Tissue SarcomaUnited States